Concord Drugs Limited

BSE: CONCORD538965ISIN INE858L01010

Healthcare
Pharmaceuticals

Share price

₹68.00+1.09 (+1.63%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹92.52
52W low: ₹59.99
Off 52W high: -26.50%
1M return: -11.60%
3M return: -5.16%
6M return: -17.73%
1Y return: -4.21%
20D avg volume: 2,919
50 DMA: ₹74.22
200 DMA: ₹76.28

Key ratios Consolidated

Market cap: ₹89.59 Cr
Current price: ₹68.00
52W high / low: ₹92.52 / ₹59.99
Face value: ₹10.00
P/E: 43.68
P/B: 1.85
EPS (TTM): ₹1.56
Book value / share: ₹36.82
ROE: —
ROCE: 5.90%
Operating margin: —
Net margin: —
Debt / equity: 0.28
Net debt: ₹13.32 Cr
Interest cover: 1.86
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 198.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	20.94	37.89	16.97	10.28	13.61	10.39	10.80	12.36	11.69	—
	0.01	0.01	0.02	0.00	0.00	0.01	0.00	0.01	0.00	—
	20.95	37.90	16.99	10.28	13.61	10.40	10.80	12.37	11.69	—
	19.40	37.15	16.69	10.01	13.45	10.34	10.27	12.30	11.65	—
	16.52	35.07	14.38	7.76	10.81	8.65	6.72	11.77	8.67	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	1.26	1.75	1.24	1.09	0.89	1.24	1.00	0.93	1.46	—
	0.40	0.40	0.34	0.49	0.49	0.61	0.50	0.47	0.45	—
	0.35	0.35	0.31	0.34	0.37	0.38	0.37	0.34	0.34	—
	0.49	0.53	0.42	0.37	0.29	0.21	0.25	0.41	0.38	—
	1.54	0.75	0.30	0.27	0.16	0.06	0.53	0.07	0.04	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.54	0.75	0.30	0.27	0.16	0.06	0.53	0.07	0.04	—
	0.43	0.22	0.08	0.08	0.04	0.02	0.30	0.02	0.01	—
	1.11	0.53	0.22	0.19	0.12	0.04	0.23	0.04	0.03	—
	0.85	0.47	0.16	0.31	0.12	0.04	0.23	0.04	0.03	—
Key metrics
	2.29	1.50	0.95	1.10	1.02	1.05	1.40	0.88	0.83	—
	10.90%	4.00%	5.60%	10.70%	7.50%	10.10%	13.00%	7.10%	7.10%	—
	5.30%	1.40%	1.30%	1.80%	0.90%	0.40%	2.10%	0.30%	0.30%	—
	—	2.10%	—	2.00%	—	1.70%	—	—	—	—
	53.90%	264.70%	57.10%	-16.80%	16.40%	—	—	—	—	—
	825.00%	1,225.00%	-4.30%	375.00%	300.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	86.08	78.74	45.24	—
	0.04	0.03	0.01	—
	86.12	78.77	45.26	—
	83.25	77.30	44.57	—
	73.73	68.03	35.81	—
	0.00	0.00	0.00	—
	5.34	4.97	4.63	—
	1.63	1.71	2.03	—
	1.35	1.37	1.43	—
	1.81	1.60	1.25	—
	2.86	1.47	0.69	—
	0.00	0.00	0.00	—
	2.86	1.47	0.69	—
	0.81	0.42	0.36	—
	2.05	1.05	0.34	—
	1.79	0.95	0.34	—
Key metrics
	5.84	4.55	4.15	—
	6.78%	5.80%	9.20%	—
	2.38%	1.30%	0.80%	—
	—	5.90%	7.00%	—
	82.53%	74.00%	—	—
	376.74%	208.80%	—	—
	—	-7.94	1.39	—
	—	-6.45	10.94	—
	—	0.28	0.50	—
	—	13.32	17.07	—
	—	198.5	252.1	—
Balance sheet
	—	74.89	65.14	—
	—	53.31	40.76	—
	—	0.28	0.12	—
	—	24.38	13.60	—
	—	25.52	25.27	—
	—	2.63	1.54	—
	—	10.94	11.57	—
	—	7.07	7.62	—
	—	21.07	26.18	—
	—	13.60	17.19	—
	—	11.79	15.87	—
	—	1.81	1.32	—
	—	48.51	34.11	—
Cash flow
	—	-6.77	3.72	—
	—	-1.13	-2.32	—
	—	8.06	-1.43	—
	—	1.17	2.33	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	20.89	35.55	16.84	10.07	13.38	0.79	10.77	11.84	6.35	—
	0.01	0.01	0.02	0.00	0.00	0.01	—	0.01	—	—
	20.90	35.56	16.86	10.08	13.38	0.80	10.77	11.85	6.35	—
	19.35	34.83	16.57	9.81	13.23	7.95	10.25	11.78	6.33	—
	16.53	31.81	14.33	7.67	10.69	6.04	8.51	9.79	3.88	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	1.25	1.73	1.22	1.08	0.87	1.53	0.95	0.86	1.05	—
	0.35	0.34	0.30	0.40	0.42	0.53	0.43	0.39	0.37	—
	0.35	0.35	0.30	0.34	0.37	0.37	0.37	0.34	0.34	—
	0.49	0.53	0.41	0.37	0.28	0.21	0.23	0.36	0.34	—
	1.54	0.73	0.29	0.29	0.15	-7.15	0.52	0.07	0.03	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	1.54	0.73	0.29	0.27	0.15	-7.15	0.52	0.07	0.03	—
	0.43	0.22	0.08	0.08	0.04	0.01	0.30	0.02	0.01	—
	1.11	0.52	0.22	0.19	0.11	-7.16	0.22	0.05	0.01	—
	0.84	0.46	0.16	0.21	0.11	0.08	0.22	0.05	0.01	—
Key metrics
	2.24	1.42	0.89	1.01	0.94	-6.25	1.32	0.80	0.74	—
	10.70%	4.00%	5.30%	10.00%	7.00%	-791.10%	12.30%	6.80%	11.70%	—
	5.30%	1.50%	1.30%	1.90%	0.80%	-906.30%	2.00%	0.40%	0.20%	—
	—	2.00%	—	1.70%	—	-17.00%	—	—	—	—
	56.10%	4,400.00%	56.40%	-14.90%	110.70%	—	—	—	—	—
	909.10%	107.30%	0.00%	280.00%	1,000.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	83.35	75.85	36.93	—
	0.04	0.03	0.01	—
	83.40	75.88	36.95	—
	80.56	74.43	36.31	—
	70.34	64.50	28.22	—
	0.00	0.00	0.00	—
	5.28	4.90	4.39	—
	1.39	1.46	1.72	—
	1.34	1.36	1.42	—
	1.80	1.58	1.13	—
	2.85	1.45	0.64	—
	0.00	0.00	0.00	—
	2.83	1.45	0.64	—
	0.81	0.41	0.35	—
	2.04	1.04	0.30	—
	1.67	0.93	0.30	—
Key metrics
	5.56	4.27	3.78	—
	6.67%	5.60%	10.20%	—
	2.45%	1.40%	0.80%	—
	—	5.40%	6.10%	—
	126.62%	105.40%	—	—
	—	246.70%	—	—
	—	-8.54	0.83	—
	—	-7.09	10.53	—
	—	0.24	0.44	—
	—	11.34	14.74	—
	—	194.7	280.6	—
Balance sheet
	—	71.85	58.58	—
	—	49.47	33.42	—
	—	0.27	0.12	—
	—	28.13	12.67	—
	—	18.35	19.13	—
	—	2.21	1.28	—
	—	10.91	11.54	—
	—	6.02	3.41	—
	—	18.02	19.62	—
	—	11.61	14.86	—
	—	9.80	13.55	—
	—	1.81	1.31	—
	—	48.51	34.11	—
Cash flow
	—	-7.37	3.16	—
	—	-1.13	-2.32	—
	—	8.65	-0.87	—
	—	1.17	2.33	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +126.62%
Profit YoY (TTM): +130.09%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +82.53%
Profit YoY (TTM): +376.74%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 45.08%

Quarter	September 2026	June 2026
Promoter %	45.08%	45.08%

Holder	Type	Holding	Previous	Change
NAGI REDDY SEELAM	Promoter	23.23%	23.23%	0.00%
MANOJKUMARREDDY SEELAM	Promoter	13.50%	13.50%	0.00%
SEELAM KONI REDDY	Promoter	8.35%	8.35%	0.00%
CHENNAMANENI SUSHMITHA	Public	8.35%	—	—
ANJANA BANGAD	Public	2.28%	2.28%	0.00%
ANURADHA BANGAD	Public	2.28%	2.28%	0.00%
VIKAS BANGAD	Public	2.28%	2.28%	0.00%
PRANALI BANGAD	Public	2.28%	2.28%	0.00%
KOMAL SHARMA	Public	1.57%	1.57%	0.00%
GANGA DEVI LOYA	Public	1.48%	1.48%	0.00%
MOHAN THODUPUNURI	Public	1.15%	1.15%	0.00%
RAJENDER KUMAR AGARWAL	Public	1.13%	1.13%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Concord Drugs Limited	90	68.00	43.68	5.90%	+82.53% TTM	+376.74% TTM	-4.21%

Filings & corporate actions

Recent announcements

Annual general meeting -Scrutinizer''s Report1 Oct 2026 · AGM/EGM / AGM
Summary Proceedings of AGM30 Sep 2026 · AGM/EGM / AGM
Closure of trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Copies of News paper publications of the Notice of the 31st AGM to be held on 30.09.20269 Sep 2026 · Company Update / Newspaper Publication
Letter to members as per regulation 36(1)(b)7 Sep 2026 · Company Update / General
Record date for Annual general meeting7 Sep 2026 · Corp. Action / Record Date
Book Closure for AGM to be held on 30.09.20267 Sep 2026 · Corp. Action / Book Closure
31st Annual Report of the Company7 Sep 2026 · Others / Reg. 34 (1) Annual Report
AGM to be held on 30.09.2026 at 09:00 AM7 Sep 2026 · AGM/EGM / AGM
Company has approved the notice and proposed to hold 31st AGM on 30.09.20267 Sep 2026 · Others / Outcome without intimation
Copy of News-paper publications for quarterly results ended 30th June 2026.12 Aug 2026 · Company Update / Newspaper Publication
Board of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 202610 Aug 2026 · Result / Financial Results
Outcome of Board meeting10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Quarterly Results3 Aug 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of SEBI (DP) Regulations13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Copy of Newspaper publication for audited results for year ended 31st March,2026.1 Jun 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance report under Regulation 24(A)29 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Financial Results for Year ending 31st March, 202629 May 2026 · Result / Financial Results
Company has approved financial results for Quarter and year ending 31st March,202627 May 2026 · Board Meeting / Outcome of Board Meeting
Company in its Board Meeting has approved financial results for period ended 31st March,202627 May 2026 · Result / Financial Results
Company in its Board Meeting has approved financial results for period ended 31st March,202627 May 2026 · Result / Financial Results
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Financial Results for year ending 31.03.202618 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....6 May 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Certificate under Reg 74(5)10 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''> <tr> <td>Sr. No.</td> <td>Particulars</td> ....10 Apr 2026 · Others / Format of the Annual Disclosure to be made by an entity identified as a LC : Annexure B2
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....10 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Closure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March, 2026.27 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
News Paper publication of Q3 results17 Feb 2026 · Company Update / Newspaper Publication
General Update16 Feb 2026 · Company Update / General
Un-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec,2025.14 Feb 2026 · Result / Financial Results
Board of Directors approved financial results for 31 st December,202514 Feb 2026 · Board Meeting / Outcome of Board Meeting
Reconstitution of Committees14 Feb 2026 · Company Update / General
Announcement under Regulation 30 of LODR14 Feb 2026 · Company Update / Retirement
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un-Audited financials Results ....2 Feb 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of SEBI (DP) regulations20 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Company has received purchase orders from various entities for supply of it''s products.30 Dec 2025 · Company Update / Award of Order / Receipt of Order
Closure of Trading Window29 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Koni Reddy25 Nov 2025 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy25 Nov 2025 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Board meetings

10 Aug 2026 Board Meeting - Financial Results